slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 234,871-234,900
Pages 10,126
Rows per page 30
Component
234,871-234,900 of 303,780
16
The slide uses a process flow diagram to explain the computational pathology workflow.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
17
Includes a Kaplan-Meier survival curve, a bar chart of prevalence by histology, and a Venn-style diagram illustrating the patient population selection process.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
18
Includes two Kaplan-Meier plots with embedded summary tables for Non-squamous/non-AGA BEP and Overall BEP populations.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
19
The slide uses a matrix-like layout to map clinical trials to patient segments. The right-hand side provides a strategic summary of the trial program's design principles.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
20
Illustrates the transition from external lab processing to in-house diagnostic capabilities.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
21
The slide features a 3D rendering of an antibody molecule.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
22
Includes references to clinical trials (CheckMate 274, AMBASSADOR, NIAGARA) and drug (Imfinzi).AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
23
Clinical trial design flow chart.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
24
The slide outlines a hierarchical testing strategy with alpha-exhaustive recycling and gatekeeping.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
25
The slide presents clinical trial baseline data for two study arms.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
26
Includes a table of clinical trial statistics (events, median EFS, HR, P-value) and a risk table.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
27
Forest plot showing hazard ratios for Imfinzi vs comparator across clinical subgroups.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
28
Includes 'No. of patients at risk' table and statistical summary table.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
29
Forest plot showing hazard ratios with 95% confidence intervals for multiple clinical subgroups.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
30
The table compares safety data across various categories of adverse events, including grade 3/4, serious AEs, and treatment-related outcomes.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
31
The chart uses a diverging bar structure to compare two treatment arms side-by-side.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
32
AstraZeneca | Investor Event Presentation Deck | 55 slidesAstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
33
Includes corporate branding and a biological illustration of an antibody-drug conjugate or similar protein structure.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
34
The slide uses a market segmentation approach to map clinical trials (NIAGARA, POTOMAC, VOLGA, NILE) to patient populations (NMIBC, MIBC, 1L mUC).AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses a three-row structure to categorize reasons for confidence: clinical evidence, safety/experience, and implementation/stakeholder alignment.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
37
The slide features a 3D rendering of an antibody molecule.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
38
The chart is a stacked area chart showing market growth by target segment (HER2, TROP2, Nectin4, etc.).AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
39
The slide uses a horizontal bar chart to represent clinical development stages for six different ADC assets.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
40
The slide compares plasma concentration over time for two different ADCs, showing the stability of the ADC vs the mAb and the low levels of free payload.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
41
Waterfall plot shows best change in target lesion size; includes CA-125 response markers.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
42
Waterfall plot shows RECIST v1.1 response criteria. Includes legend for dose levels and callout boxes for clinical outcomes.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
43
The slide features a stylized 3D rendering of a bispecific antibody molecule.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
45
WCLC conference presentation slide. Includes waterfall plot and summary table of ORR and treatment continuation.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
47
Waterfall plot shows tumor shrinkage; includes key clinical metrics (ORR, mPFS) and safety/future trial status.AstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit
48
AstraZeneca | Investor Event Presentation Deck | 55 slidesAstraZeneca | Investor Event Presentation Deck | 55 slides · AstraZeneca
Conference presentation Investor relations 1 hit